文献速递甲状腺与浅表头颈USPET

五种超声风险分层系统对局灶性[18F]FDG-PET/CT甲状腺偶发瘤恶性诊断的性能

Diagnostic performances of five US risk stratification systems for malignancy in focal [18F]FDG-PET/CT thyroid incidentalomas.
PubMed 文献 · Eur Radiol · 2025-09-22

本回顾性队列研究纳入216例患者共236个[18F]FDG-PET/CT甲状腺偶发瘤,评估五种超声风险分层系统(US-RSS)结合活检标准的恶性诊断性能。结果显示中危偶发瘤恶性风险(33.8-48.2%)高于各系统建议值(p<0.01),仅C-TIRADS低危组恶性风险显著升高(35.0%,p<0.01);ACR-TIRADS特异性最高(50.0%)且不必要活检率最低(30.2%,p<0.01)。

要点

  • 中危甲状腺偶发瘤恶性风险为33.8-48.2%,高于所有US-RSS建议的恶性风险(p<0.01)。
  • C-TIRADS低危组恶性风险为35.0%,显著高于建议值(p<0.01)。
  • ACR-TIRADS特异性最高(50.0%),不必要活检率最低(30.2%,p<0.01)。

核心结论

  • 中危甲状腺偶发瘤在各US-RSS中恶性风险均较高,低危组仅C-TIRADS显著升高;US-RSS虽可减少不必要活检,但European-TIRADS、ACR-TIRADS和C-TIRADS对侵袭性恶性肿瘤的敏感度相对较低。

研究设计与样本

  • 回顾性队列研究,纳入216例患者共236个[18F]FDG-PET/CT甲状腺偶发瘤,其中208例(96.3%)为肿瘤患者,评估五种US-RSS结合活检标准的诊断性能。

诊断标准与关键数值

  • 中危甲状腺偶发瘤恶性风险为33.8-48.2%,高于各US-RSS建议值(p<0.01)。
  • C-TIRADS低危组恶性风险为35.0%(>20%,p<0.01)。
  • 在189个>1 cm的偶发瘤中,ATA系统和Korean-TIRADS对总体恶性肿瘤敏感度最高(97.3%),对侵袭性恶性肿瘤敏感度最高(100%);其他US-RSS对总体和侵袭性恶性肿瘤敏感度分别为86.7-90.7%和80.0-86.7%。
  • ACR-TIRADS特异性最高(50.0%),不必要活检率最低(30.2%,p<0.01)。
  • 联合SUVmax后ACR-TIRADS敏感度提高至96.0%(p=0.02),但不必要活检率也增高(p<0.01)。

临床应用与阅片要点

  • 对[18F]FDG-PET/CT发现的甲状腺偶发瘤,可采用US-RSS进行恶性风险分层以减少不必要活检。
  • 作者指出,基于肿瘤患者的临床背景,European-TIRADS和ACR-TIRADS的中危结节以及C-TIRADS的低危结节可能需要更低的活检尺寸 cutoff。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study assessed the risk of malignancy (ROM) of nodules classified by five US risk stratification systems (US-RSSs) and evaluated the diagnostic performances of US-RSSs with biopsy criteria for diagnosing malignancy in focal [18F]fluorodeoxyglucose (FDG)-PET/CT thyroid incidentalomas (TIs).

MATERIALS AND METHODS: This retrospective cohort study included 216 patients with 236 [18F]FDG-PET/CT TIs, of whom 208 (96.3%) were oncology patients. The primary outcome included the diagnostic performances of five US-RSSs with biopsy criteria for diagnosing malignant tumors. Secondary outcomes included the ROM of nodules classified by US-RSSs and the diagnostic performance of US-RSS criteria combined with maximum standardized uptake value (SUVmax).

RESULTS: The malignancy risk of intermediate-risk TIs was higher (33.8-48.2%) than the suggested ROM across all RSSs (p < 0.01). Low-risk category TIs had a significantly higher ROM (> 20%) only in Chinese-Thyroid Imaging Reporting and Data System (C-TIRADS; 35.0%, p < 0.01). The sensitivity for overall and aggressive malignancies was highest (97.3% and 100%, respectively) in the American Thyroid Association system and Korean-TIRADS, but lower (86.7-90.7% and 80.0-86.7%, respectively) in other RSSs for 189 TIs > 1 cm. American College of Radiology (ACR)-TIRADS showed the highest specificity (50.0%) and lowest unnecessary biopsy rate (30.2%, p < 0.01). Combined SUVmax-US-RSS criteria demonstrated increased sensitivity in ACR-TIRADS (96.0%, p = 0.02), but also showed greater unnecessary biopsy rates (p < 0.01).

CONCLUSION: Intermediate-risk TIs had greater ROM across RSSs, while low-risk TIs showed a significant increase only in C-TIRADS. Although US-RSSs can reduce unnecessary biopsies, European-TIRADS, ACR-TIRADS, and C-TIRADS demonstrated relatively lower sensitivity for aggressive malignancies.

KEY POINTS: Question The diagnostic performance of US risk stratification systems (US-RSS) from various professional societies remains unestablished in the assessment of focal [18F]fluorodeoxyglucose (FDG)-PET/CT thyroid incidentalomas. Findings While US-RSSs reduce unnecessary biopsies, European-, American College of Radiology-, and Chinese-thyroid imaging reporting and data systems (TIRADS) demonstrated relatively lower sensitivity for aggressive malignancies. Clinical relevance US-RSSs stratify malignancy risk in focal [18F]FDG-PET/CT incidentalomas, but lower biopsy size cutoffs may be needed for intermediate-risk nodules in European- and American College of Radiology-TIRADS and low-risk nodules in Chinese-TIRADS, based on oncology patients' clinical context.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Shin CY, Ahn HS, Na DG, et al. Diagnostic performances of five US risk stratification systems for malignancy in focal [18F]FDG-PET/CT thyroid incidentalomas. Eur Radiol. 2025. PMID: 40981993. doi:10.1007/s00330-025-12008-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。